Profund Advisors LLC Buys 26,424 Shares of IDEAYA Biosciences, Inc. $IDYA

Profund Advisors LLC grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 127.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,115 shares of the company’s stock after buying an additional 26,424 shares during the quarter. Profund Advisors LLC owned approximately 0.05% of IDEAYA Biosciences worth $1,629,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Iron Triangle Partners LP acquired a new position in IDEAYA Biosciences in the 3rd quarter worth about $7,347,000. Envestnet Asset Management Inc. boosted its stake in shares of IDEAYA Biosciences by 174.0% during the third quarter. Envestnet Asset Management Inc. now owns 299,032 shares of the company’s stock valued at $8,137,000 after purchasing an additional 189,877 shares in the last quarter. General American Investors Co. Inc. grew its holdings in shares of IDEAYA Biosciences by 7.7% during the third quarter. General American Investors Co. Inc. now owns 280,261 shares of the company’s stock worth $7,626,000 after purchasing an additional 20,000 shares during the last quarter. Candriam S.C.A. increased its stake in shares of IDEAYA Biosciences by 10.8% in the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after buying an additional 98,567 shares during the period. Finally, Cinctive Capital Management LP increased its stake in shares of IDEAYA Biosciences by 193.9% in the third quarter. Cinctive Capital Management LP now owns 49,946 shares of the company’s stock valued at $1,359,000 after buying an additional 32,953 shares during the period. 98.29% of the stock is currently owned by institutional investors.

Insider Transactions at IDEAYA Biosciences

In other news, Director Jeffrey Stein bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were acquired at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the acquisition, the director directly owned 54,281 shares in the company, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.70% of the stock is currently owned by insiders.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA opened at $29.65 on Thursday. IDEAYA Biosciences, Inc. has a fifty-two week low of $18.25 and a fifty-two week high of $39.28. The company has a 50 day simple moving average of $31.15 and a two-hundred day simple moving average of $32.83. The company has a market capitalization of $2.61 billion, a PE ratio of -18.53 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the prior year, the business earned ($0.82) EPS. The business’s revenue for the quarter was down 39.4% on a year-over-year basis. Research analysts predict that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a research report on Monday, April 13th. Wells Fargo & Company lifted their price target on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Citigroup boosted their price objective on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Tuesday, April 21st. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.69.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.